Citigroup Inc Moon Lake Immunotherapeutics Transaction History

Citigroup Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$36.35 - $63.02 $82,332 - $142,740	2,265 Added 7078.13%	2,297 $138,000
Q3 2023 Nov 09, 2023	SELL	$48.35 - $61.26 $27,607 - $34,979	-571 Reduced 94.69%	32 $1,000
Q2 2023 Aug 10, 2023	SELL	$19.01 - $51.79 $1.46 Million - $3.97 Million	-76,673 Reduced 99.22%	603 $30,000
Q1 2023 May 11, 2023	SELL	$11.03 - $23.7 $982,122 - $2.11 Million	-89,041 Reduced 53.54%	77,276 $1.65 Million
Q4 2022 Feb 09, 2023	BUY	$7.05 - $10.5 $50,971 - $75,915	7,230 Added 4.54%	166,317 $1.75 Million
Q2 2022 Aug 10, 2022	BUY	$4.69 - $13.25 $746,118 - $2.11 Million	159,087 New	159,087 $835,000

126

58.2M

52.2K

38K

Ticker MLTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,925,600
Market Cap $1.74B
Description
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or rad...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.